Vivos Therapeutics (NASDAQ: VVOS) founder and chief medical officer, Dr. G. Dave Singh, DMD, PhD, DDSc, has written a new book with the intent of assisting doctors and dentists in better understanding how to address underlying craniofacial conditions that impact a patient’s overall airway, breathing and sleep health. Titled “Pneumopedics and Craniofacial Epigenetics,” the book covers craniofacial growth and developmental genetics, and addresses the connection between dentofacial anomalies and developmental deficiencies closely associated with downstream conditions such as obstructive sleep apnea (“OSA”). In addition, the book, which is available on Amazon, solidifies the scientific and biological foundation upon which VVOS’s proprietary approach is built. Vivos is focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including OSA. The company’s novel approach involves the skills of dentists who have been specially trained and the first nonsurgical, noninvasive and cost-effective treatment for people with mild-to-moderate OSA. “In many respects, this book is the culmination of my life’s work and research, starting with the theoretical foundation set forth in the Spatial Matrix Hypothesis that I first published in 2004 and continuing through the ensuing years with numerous confirmational patient studies in clinical settings,” said Vivos founder and chief medical officer Dr. G. Dave Singh in the press release. “Having the opportunity to bring this technology to the world to help patients who are suffering continues to be my mission, and the overarching goal with this book is to spread the word far and wide about how this technology can truly make a difference in how we approach thinking about and treating downstream health conditions like OSA moving forward.”
To view the full press release, visit https://ibn.fm/E0GYn
About Vivos Therapeutics Inc.
Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for people with mild-to-moderate OSA. or significantly reduce symptoms and conditions associated with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in treating more than 17,000 patients worldwide by more than 1,200 dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology for Home Sleep Testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using the Vivos System. For more information about this company, visit www.VivosLife.com.
NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
